Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Latest From Alcon Inc.

Consumer Health Brands Will Be Included In Bausch's Spin-Out Of Bausch Part Of Company

“The spin-off will establish two separate companies, a fully integrated, pure play, eye health company built on the iconic Bausch Health brand and a long history of innovation, and an international diversified pharmaceutical company with leading physicians in gastroenterology, dermatology, aesthetics, neurology and an international pharma business,” says CEO Joseph Papa.

M & A OTC Drugs

Bausch To Spin-Out The Bausch Part Of Its Business

The company formerly known as Valeant, put together by a series of mergers, is ready to spin out the legacy Bausch + Lomb eyecare business that it used in its rebranding. 

Business Strategies Sales & Earnings

With Pataday Extra Strength, Alcon Eyes Consumers Looking For OTC 24-Hour Eye Allergy Remedy

Pataday Once Daily Relief Extra Strength is the same formulation as Novartis' Rx Pazeo. It will be the first OTC eye drop indicated for allergy itch with 24-hour efficacy, available online in September and through retailers in early 2021.

Prescription To Otc Switch FDA

FTC Narrowly Okays AbbVie/Allergan Merger As Dissenter Slams Divestitures To AstraZeneca, Nestlé

Commissioner Chopra says candy maker Nestlé cannot take Allergans place in the market and AstraZeneca would get a windfall without paying anything for a valuable drug development project. AbbVie/Allergan must divest enzyme replacement therapies Zenpap and Viokace to Nestlé and investigational IL-23 inhibitor brazikumab to AstraZeneca. 

M & A Enforcement
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Nutraceuticals
    • OTC, Consumer
  • Medical Devices
    • Consumables, Central Supplies
    • Implantable Devices
    • Surgical Equipment & Devices
  • Other Names / Subsidiaries
    • Alcon Laboratories, Inc.
    • Alcon Universal SA,
UsernamePublicRestriction

Register